Read by QxMD icon Read

Fusion biopsy prostate

Dennis Robins, Michael Lipsky, Arindam RoyChoudry, Sven Wenske
OBJECTIVE: To investigate patient pain perception from receiving MRI fusion guided prostate biopsy (FBx) in addition to transrectal ultrasound guided template biopsy (TBx) versus pain from standard TBx alone. MATERIALS AND METHODS: Patients undergoing FBx+TBx or TBx alone from April 2016 through February 2017 completed a validated pain survey after biopsy. Responses were graded from 0-10 (0: no pain/willing to return for repeat procedure; 10: excruciating pain/not willing to return for repeat procedure if necessary)...
March 12, 2018: Urology
Jennifer B Gordetsky, Benjamin Saylor, Sejong Bae, Jeffrey W Nix, Soroush Rais-Bahrami
OBJECTIVES: To assess management choices in patients who undergo magnetic resonance imaging (MRI)/ultrasound (MRI/US) fusion-guided prostate biopsy compared to patients who undergo systematic biopsy. METHODS: We compared men who underwent MRI/US fusion-guided prostate biopsy to those who underwent systematic 12-core biopsy from 2014 to 2016. Patient demographics and pathologic findings were reviewed. The highest grade group per case was considered for analysis. RESULTS: Follow-up was available on 133 patients who underwent MRI/US targeted biopsy and 215 patients who underwent systematic biopsy...
March 8, 2018: Urologic Oncology
Amirali Salmasi, Jonathan Said, Alan W Shindel, Pooria Khoshnoodi, Ely R Felker, Anthony E Sisk, Tristan Grogan, Debbie McCullough, John Bennett, Helen Bailey, H Jeffrey Lawrence, David A Elashoff, Leonard S Marks, Steven S Raman, Phillip G Febbo, Robert E Reiter
PURPOSE: Multiparametric MRI (mpMRI) and biopsy-based molecular tests such as the 17-gene Oncotype DX® Genomic Prostate Score™ (GPS) assay are increasingly used to improve risk stratification in men with clinically localized prostate cancer (PCa). The GPS assay was previously shown to be a significant independent predictor of adverse pathology (AP) at radical prostatectomy (RP) in men diagnosed with systematic biopsies only. We therefore investigated the ability of GPS to predict AP in the setting of MRI-guided prostate biopsy...
March 7, 2018: Journal of Urology
Neal Patel, Joshua A Halpern, Khushabu Kasabwala, Eliza Cricco-Lizza, Michael Herman, Daniel Margolis, Chris Xu, Brian D Robinson, Yi Wang, Timothy Mcclure, Jim C Hu
PURPOSE: To determine the association between multiple regions of interest (ROI) on pre-biopsy magnetic resonance imaging (MRI) and the detection of clinically significant prostate cancer (CSPC) in men undergoing MRI ultrasound fusion biopsy (Fbx). METHODS: We performed a retrospective, single-institution analysis of men who underwent fusion biopsy. Men with prior positive biopsies, MRIs performed at outside institutions and MRIs prior to release of Prostate Imaging Reporting and Data System (PI-RADS) version 2 were excluded, resulting in 381 subjects...
March 5, 2018: Journal of Urology
Pierre Graff, Daniel Portalez, Amélie Lusque, Thomas Brun, Richard Aziza, Jonathan Khalifa, Mathieu Roumiguié, Marie-Laure Quintyn Ranty, Thomas Filleron, Jean-Marc Bachaud, Bernard Malavaud
PURPOSE: Focal therapy of prostate cancer requires precise positioning of therapeutic agents within well-characterized index tumors (ITs). We assessed the feasibility of low-dose-rate ultrafocal brachytherapy. METHODS AND MATERIALS: The present study was an institutional review board-approved European Clinical Trials Database-registered phase II protocol. Patients referred (October 2013 to August 2016) for active surveillance (prostate-specific antigen <10 ng/mL, cT1c-cT2a, Gleason score on referring biopsy specimens ≤6 (3+3), ≤3 positive biopsy cores, ≤50% of cancer) were preselected...
February 2, 2018: International Journal of Radiation Oncology, Biology, Physics
Stig Müller, Gunder Lilleaasen, Tor Erik Sand, Lars Løfsgaard, Manuela Estop-Garanto, Dan Helgø, Peter Sund, Vegard Mygland
PURPOSE: Since January 2015, all men referred to urologists in Norway due to elevated PSA or other suspicion of prostate cancer underwent multiparametric MRI (mpMRI) before prostate biopsy. At our hospital, patients and the initial MRI were assessed by an urologist and if deemed necessary, patients were referred to another institution for MR/US fusion biopsies. Before MR/US biopsy, patients underwent a second mpMRI. Since we noticed disagreement of these two mpMRIs before biopsy, we retrospectively assessed the level of agreement between the two mpMRIs from the two institutions...
March 5, 2018: World Journal of Urology
Hiram Shaish, Whitney Feltus, Jonathan Steinman, Elizabeth Hecht, Sven Wenske, Firas Ahmed
PURPOSE: The aim of this study was to assess the impact of a structured reporting template on adherence to the Prostate Imaging Reporting and Data System (PI-RADS) version 2 lexicon and on the diagnostic performance of prostate MRI to detect clinically significant prostate cancer (CS-PCa). METHODS: An imaging database was searched for consecutive patients who underwent prostate MRI followed by MRI-ultrasound fusion biopsy from October 2015 through October 2017. The initial MRI reporting template used included only subheadings...
March 2, 2018: Journal of the American College of Radiology: JACR
Alison D Sheridan, Sameer K Nath, Sanjay Aneja, Jamil S Syed, Jay Pahade, Mahan Mathur, Preston Sprenkle, Jeffrey C Weinreb, Michael Spektor
OBJECTIVE: The purpose of this study was to determine imaging and clinical features associated with Prostate Imaging Reporting and Data System (PI-RADS) category 5 lesions identified prospectively at multiparametric MRI (mpMRI) that were found benign at MRI-ultrasound fusion targeted biopsy. MATERIALS AND METHODS: Between January 2015 and July 2016, 325 men underwent prostate mpMRI followed by MRI-ultrasound fusion targeted biopsy of 420 lesions prospectively identified and assessed with PI-RADS version 2...
February 28, 2018: AJR. American Journal of Roentgenology
S Tavolaro, P Mozer, M Roupret, E Comperat, F Rozet, E Barret, S Drouin, C Vaessen, O Lucidarme, O Cussenot, F Boudghène, R Renard-Penna
PURPOSE: The purpose of this study was to evaluate precise location criteria on magnetic resonance imaging (MRI) to improve detection of transition zone (TZ) and anterior stroma (AS) prostate cancers using targeted MRI/transrectal ultrasound fusion biopsies as a reference standard. MATERIAL AND METHODS: Ninety-six men (mean age: 65 years±7.7 [SD] [range: 46-83 years]) with an elevated prostate-specific antigen (PSA) (PSA≥4ng/mL) who underwent standard and targeted biopsies on a TZ/AS suspicious lesion were included...
February 21, 2018: Diagnostic and Interventional Imaging
Ashkan Mortezavi, Olivia Märzendorfer, Olivio F Donati, Gianluca Rizzi, Niels J Rupp, Marian S Wettstein, Oliver Gross, Tullio Sulser, Thomas Hermanns, Daniel Eberli
PURPOSE: To evaluate the diagnostic accuracy of mpMRI and mpMRI / transrectal ultrasound (TRUS) fusion-guided targeted biopsy (FTB) against transperineal template saturation prostate biopsy (TTSPB) for the detection of prostate cancer (PCa). PATIENTS AND METHODS: Retrospective analysis of 415 men consecutively presenting for prostate biopsy between 11/2014 and 9/2016 at our tertiary care centre. MpMRI (3-Tesla, without endorectal coil) was performed followed by TTSPB with the BiopSee® fusion system...
February 20, 2018: Journal of Urology
Sherif Mehralivand, Joanna H Shih, Soroush Rais-Bahrami, Aytekin Oto, Sandra Bednarova, Jeffrey W Nix, John V Thomas, Jennifer B Gordetsky, Sonia Gaur, Stephanie A Harmon, Mohummad Minhaj Siddiqui, Maria J Merino, Howard L Parnes, Bradford J Wood, Peter A Pinto, Peter L Choyke, Baris Turkbey
Importance: Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. Objective: To determine whether an MRI-based prediction model can reduce unnecessary biopsies in patients with suspected prostate cancer. Design, Setting, and Participants: Patients underwent MRI, MRI-TRUS fusion-guided biopsy, and 12-core systematic biopsy in 1 session...
February 22, 2018: JAMA Oncology
Ahmad Algohary, Satish Viswanath, Rakesh Shiradkar, Soumya Ghose, Shivani Pahwa, Daniel Moses, Ivan Jambor, Ronald Shnier, Maret Böhm, Anne-Maree Haynes, Phillip Brenner, Warick Delprado, James Thompson, Marley Pulbrock, Andrei S Purysko, Sadhna Verma, Lee Ponsky, Phillip Stricker, Anant Madabhushi
BACKGROUND: Radiomic analysis is defined as computationally extracting features from radiographic images for quantitatively characterizing disease patterns. There has been recent interest in examining the use of MRI for identifying prostate cancer (PCa) aggressiveness in patients on active surveillance (AS). PURPOSE: To evaluate the performance of MRI-based radiomic features in identifying the presence or absence of clinically significant PCa in AS patients. STUDY TYPE: Retrospective...
February 22, 2018: Journal of Magnetic Resonance Imaging: JMRI
Alexandre Fourcade, Charlotte Payrard, Valentin Tissot, Marie-Aimée Perrouin-Verbe, Nicolas Demany, Sophie Serey-Effeil, Pierre Callerot, Jean-Baptiste Coquet, Laurent Doucet, Charles Deruelle, Vincent Joulin, Michel Nonent, Georges Fournier, Antoine Valeri
OBJECTIVE: Compared with standard systematic transrectal ultrasound (TRUS)-guided biopsies (SBx), targeted biopsies (TBx) using magnetic resonance imaging (MRI)/TRUS fusion could increase the detection of clinically significant prostate cancer (PCa-s) and reduce non-significant PCa (PCa-ns). This study aimed to compare the performance of the two approaches. MATERIALS AND METHODS: A prospective, single-center study was conducted on all consecutive patients with PCa suspicion who underwent prebiopsy multiparametric MRI (mpMRI) using the Prostate Imaging Reporting and Data System (PI-RADS)...
February 20, 2018: Scandinavian Journal of Urology
Udit Singhal, Yugang Wang, James Henderson, Yashar S Niknafs, Yuanyuan Qiao, Amy Gursky, Alexander Zaslavsky, Jae-Seung Chung, David C Smith, R Jeffrey Karnes, S Laura Chang, Felix Y Feng, Ganesh S Palapattu, Russell S Taichman, Arul M Chinnaiyan, Scott A Tomlins, Todd M Morgan
The trend towards precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer related genes...
February 16, 2018: Molecular Cancer Research: MCR
Ester Bonmati, Yipeng Hu, Barbara Villarini, Rachael Rodell, Paul Martin, Lianghao Han, Ian Donaldson, Hashim U Ahmed, Caroline M Moore, Mark Emberton, Dean C Barratt
PURPOSE: Image-guided systems that fuse magnetic resonance imaging (MRI) with three-dimensional (3D) ultrasound (US) images for performing targeted prostate needle biopsy and minimally-invasive treatments for prostate cancer are of increasing clinical interest. To date, a wide range of different accuracy estimation procedures and error metrics have been reported, which makes comparing the performance of different systems difficult. METHODS: A set of 9 measures are presented to assess the accuracy of MRI-US image registration, needle positioning, needle guidance, and overall system error, with the aim of providing a methodology for estimating the accuracy of instrument placement using a MR/US-guided transperineal approach...
February 14, 2018: Medical Physics
Andrew B Rosenkrantz, Jovan Begovic, Antonio Pires, Eugene Won, Samir S Taneja, James S Babb
PURPOSE: To assess the effect on reader performance of an interactive case-based online tutorial for prostate magnetic resonance imaging (MRI) interpretation using Prostate Imaging and Reporting Data System (PI-RADS). METHODS: An educational website was developed incorporating scrollable multiparametric prostate MRI examinations with annotated solutions based on PI-RADS version 2. Three second-year radiology residents evaluated a separate set of 60 prostate MRI examinations both before and after review of the online case material, identifying and scoring dominant lesions...
January 10, 2018: Current Problems in Diagnostic Radiology
Saradwata Sarkar, Sadhna Verma
Conventional ultrasound-guided prostate biopsies have multiple limitations leading to underdetection of clinically significant prostate cancer (PCa) and overdetection of clinically insignificant PCa. Multiparametric MR imaging of the prostate offers better localization of prostatic tumors in comparison with ultrasound imaging and can help address these limitations. MR imaging-identified lesions can be targeted for biopsy directly in-gantry or indirectly using a fusion of MR imaging and ultrasound imaging. The fusion may be performed by the operator visually or using a software fusion device...
March 2018: Radiologic Clinics of North America
Egesta Lopci, Alberto Saita, Massimo Lazzeri, Giovanni Lughezzani, Piergiuseppe Colombo, Nicolò Maria Buffi, Rodolfo Hurle, Katia Marzo, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Pasquale Cardone, Angelo Castello, Davide Maffei, Luca Balzarini, Arturo Chiti, Giorgio Guazzoni, Paolo Casale
BACKGROUND: 68 Ga-PSMA PET/CT may represent the most promising imaging modality for identification and risk stratification of prostate cancer (PCa) in patients with contraindications to or negative multiparametric MRI (mpMRI). METHODS: This prospective observational study analyzed68 Ga-PSMA PET/CT in a selected group of patients with persistently elevated PSA and/or PHI (prostate health index) suspicious for PCa, negative digital rectal examination, and at least one negative biopsy...
January 31, 2018: Journal of Urology
Susan Prendeville, Mark Gertner, Manjula Maganti, Melania Pintilie, Nathan Perlis, Ants Toi, Andrew J Evans, Antonio Finelli, Theodorus H van der Kwast, Sangeet Ghai
PURPOSE: The aim of this study was to compare biopsy detection of intraductal (IDC) and cribriform (CR) pattern invasive prostate carcinoma (PCa) in mpMRI positive and negative regions of the prostate. MATERIAL AND METHODS: A prospectively maintained single institution database was queried to identify patients who underwent mpMRI/US fusion targeted biopsy (MRI-TBx) and concurrent systematic sextant biopsy of MRI negative regions (SMN-Bx) between January 2013 and May 2016...
January 31, 2018: Journal of Urology
Christine L Barnett, Matthew S Davenport, Jeffrey S Montgomery, John T Wei, James E Montie, Brian T Denton
OBJECTIVE: To determine how best to use MRI and targeted MR/ultrasound fusion biopsy for early detection of prostate cancer in men with elevated PSA and whether it can be cost-effective. METHODS: A Markov model of prostate cancer onset and progression was developed to estimate health and economic consequences of prostate cancer screening with MRI. Men were screened with prostate-specific antigen (PSA) from ages 55 to 69. Men with elevated PSA (>4 ng/mL) received an MRI, followed by targeted fusion or combined (standard + targeted fusion) biopsy on positive MRI, and standard or no biopsy on negative MRI...
February 1, 2018: BJU International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"